We obtained and published FDA FOIA documents this summer exposing this upcoming label change.
On September 27, 2023, Ozempic, a type 2 diabetes drug that is prescribed off label to help with weight loss is updating its label to warn of the risk of intestinal blockage, supporting lawsuit claims currently pending. Our firm obtained the FDA internal documents exposing this risk through FOIA and made them available to the public in June of 2023.
Here are links to the documents produceed to our firm by FDA through our FOIA requests: (FDA email to GLP-1 makers confirming risk): https://www.dropbox.com/s/gak9imkc80v0jbc/23002845_enc3_sdm.pdf?dl=0 (FDA correspondence to GLP-1 makers requiring label change): https://www.dropbox.com/s/jvcl4qryfmfrgez/23002845_enc2_sdm.pdf?dl=0 (FDA Pharmacovigilance Review of GLP-1 drugs dated November 2022 confirming risk): https://www.dropbox.com/s/4wan1kgyog5t40v/23002845_enc1_sdm.pdf?dl=0 Studies also link these blockbuster drugs to serious injuries such as gallbladder disease. If you or a loved one suffered serious adverse events such as intestinal obstruction or acute gallbladder disease from Ozempic, Rybelsus, Victoza, Tulicity, and Mounjaro, please feel free to contact the Levensten Law Firm at 215-545-5600 to learn more about your rights to file a claim for compensation for your injuries.